It can reduce the accumulation of hepatic fat, enhance adiponectin secretion, increase endothelial progenitor cell proliferation, and increase PPAR-γ expression, which is probably responsible for the therapeutic effect of YCHD on NAFLD [92, 93]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.